発行書籍・論文

発行書籍

原発性肝癌取扱い規約(日本語版)

発刊書籍名 発行所 価 格
臨床・病理、原発性肝癌取扱い規約 第6版補訂版
2019年3月発刊
金原出版株式会社
03-3811-7184
3,500円(税別)
臨床・病理、原発性肝癌取扱い規約 第6版
2015年7月発刊
金原出版株式会社
03-3811-7184
3,500円(税別)
臨床・病理、原発性肝癌取扱い規約 第5版補訂版
2009年6月発刊
金原出版株式会社
03-3811-7184
3,500円(税別)
臨床・病理、原発性肝癌取扱い規約 第5版
2008年2月発刊
金原出版株式会社
03-3811-7184
3,500円(税別)
臨床・病理、原発性肝癌取扱い規約 第4版
2000年11月発刊
金原出版株式会社
03-3811-7184
3,500円(税別)
臨床・病理、原発性肝癌取扱い規約 第3版補訂版
1992年2月発刊
金原出版株式会社
03-3811-7184
臨床・病理、原発性肝癌取扱い規約 第2版補訂版
1987年7月発刊
金原出版株式会社
03-3811-7184
臨床・病理、原発性肝癌取扱い規約 第1版補訂版
1983年6月発刊
金原出版株式会社
03-3811-7184

原発性肝癌取扱い規約(英語版)

発刊書籍名 発行所 価 格
General rules for the clinical and pathological study of primary liver cancer
原発性肝癌取扱い規約(英語版)3版 2010年8月発刊
金原出版株式会社
03-3811-7184
4,100円(税別)
General rules for the clinical and pathological study of primary liver cancer 原発性肝癌取扱い規約(英語版)2版 2003年10月発刊 金原出版株式会社
03-3811-7184
General rules for the clinical and pathological study of primary liver cancer 原発性肝癌取扱い規約(英語版)1版 1997年10月発刊 金原出版株式会社
03-3811-7184

肝内胆管癌診療ガイドライン

発刊書籍名 発行所 価 格
肝内胆管癌診療ガイドライン2021年版 金原出版株式会社
03-3811-7184
3,000円(税別)

全国原発性肝癌追跡調査報告

発刊書籍名 発行所 価 格
第23回全国原発性肝癌追跡調査報告(2014-2015) 日本肝癌研究会 10,000円
第22回全国原発性肝癌追跡調査報告(2012-2013) 日本肝癌研究会 10,000円
第21回全国原発性肝癌追跡調査報告(2010-2011) 日本肝癌研究会 10,000円
第20回全国原発性肝癌追跡調査報告(2008-2009) 日本肝癌研究会
第19回全国原発性肝癌追跡調査報告(2006-2007) 日本肝癌研究会
第18回全国原発性肝癌追跡調査報告(2004-2005) 日本肝癌研究会
第17回全国原発性肝癌追跡調査報告(2002-2003) 日本肝癌研究会
第16回全国原発性肝癌追跡調査報告(2000-2001) 日本肝癌研究会
第15回全国原発性肝癌追跡調査報告(1998-1999) 日本肝癌研究会
第14回全国原発性肝癌追跡調査報告(1996-1997) 日本肝癌研究会
第13回全国原発性肝癌追跡調査報告(1994-1995) 日本肝癌研究会
第12回全国原発性肝癌追跡調査報告(1992-1993) 日本肝癌研究会
第11回全国原発性肝癌追跡調査報告(1990-1991) 日本肝癌研究会
第10回全国原発性肝癌追跡調査報告(1988-1989) 日本肝癌研究会
第9回全国原発性肝癌追跡調査報告(1986-1987) 日本肝癌研究会
第8回全国原発性肝癌追跡調査報告(1984-1985) 日本肝癌研究会
第7回全国原発性肝癌追跡調査報告(1982-1983) 日本肝癌研究会
第6回全国原発性肝癌追跡調査報告(1980-1981) 日本肝癌研究会
第5回全国原発性肝癌追跡調査報告(1978-1979) 日本肝癌研究会

日本肝癌研究会の追跡調査による論文

追跡調査報告(国内論文)

  1. 村上文夫、岡村純、他:肝疾患の外科治療法.診療 23:265, 1970.
  2. 石川浩一、小坂淳夫:原発性肝癌切除例の手術成績.肝臓 14:409-410, 1973.
  3. 石川浩一:原発性肝癌症例に関する追跡調査-第3報-.肝臓 17:460-465, 1976.
  4. 日本肝癌研究会:原発性肝癌に関する追跡調査-第4報-.肝臓 20:433-441, 1979.
  5. 日本肝癌研究会:原発性肝癌に関する追跡調査-第5報-.肝臓 23:675-681, 1982.
  6. 日本肝癌研究会:原発性肝癌に関する追跡調査-第6報-.肝臓 26:254-262, 1985.
  7. 日本肝癌研究会:原発性肝癌に関する追跡調査-第7報-.肝臓 27:1161-1169, 1986.
  8. 日本肝癌研究会:原発性肝癌に関する追跡調査-第8報-.肝臓 29:1619-1626, 1988.
  9. 日本肝癌研究会:原発性肝癌に関する追跡調査-第9報-.肝臓 32:1138-1147, 1991.
  10. 日本肝癌研究会:原発性肝癌に関する追跡調査-第10報-.肝臓 34:805-813, 1993.
  11. 日本肝癌研究会:原発性肝癌に関する追跡調査-第11報-.肝臓 36:208-218, 1995.
  12. 日本肝癌研究会:原発性肝癌に関する追跡調査-第12報-.肝臓 38:317-330, 1997.
  13. 日本肝癌研究会:原発性肝癌に関する追跡調査-第13報-.肝臓 40:288-300, 1999.
  14. 日本肝癌研究会:第14回全国原発性肝癌追跡調査報告(1996-1997).肝臓 41:799-811, 2000.
  15. 日本肝癌研究会:第15回全国原発性肝癌追跡調査報告(1998-1999).肝臓 44:157-175, 2003.
  16. 日本肝癌研究会:第16回全国原発性肝癌追跡調査報告(2000-2001).肝臓 46:234-254, 2005.
  17. 日本肝癌研究会:第17回全国原発性肝癌追跡調査報告(2002-2003).肝臓 48: 117-140, 2007.
  18. 日本肝癌研究会:第18回全国原発性肝癌追跡調査報告(2004-2005).肝臓 51: 460-484, 2010.
  19. 日本肝癌研究会:第19回全国原発性肝癌追跡調査報告(2004-2005).肝臓 57: 45-73, 2016.
  20. 日本肝癌研究会:第20回全国原発性肝癌追跡調査報告(2008-2009).肝臓 60: 258-293, 2016.
  21. 日本肝癌研究会:第21回全国原発性肝癌追跡調査報告(2008-2009).肝臓 61: 645-691, 2020.
  22. 日本肝癌研究会:第22回全国原発性肝癌追跡調査報告(2012-2013).肝臓 62: 251-299, 2021.

追跡調査報告(国外論文)

  1. Okuda K: Liver Cancer Study Group of Japan: Primary liver cancers in Japan. Cancer 45:2663-2669, 1980.
  2. Liver Cancer Study Group of Japan: Primary liver cancer in Japan. Cancer 54:1747-1755, 1984.
  3. Liver Cancer Study Group of Japan: Primary liver cancer in Japan-Sixth report-. Cancer 60:1400-1411, 1987.
  4. Liver Cancer Study Group of Japan: Primary liver cancer in Japan. Ann Surg 211:277-287, 1990.
  5. Primary Liver Cancer in Japan. Eds. T. Tobe et al: Springer-Verlag Tokyo, Berlin, Heidelberg, New York, London, Paris, Hong Kong, Barcelona 1992.
  6. Ikai I, Itai Y, Okita K, Omata M, Kojiro M, Kobayashi K, Nakanuma Y, Futagawa S, Makuuchi M, Yamaoka Y. Report of the 15th follow-up survey of primary liver cancer. Hepatol Res 28:21-29, 2004.
  7. Ikai I, Arii S, Ichida T, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y. Report of the 16th follow-up survey of primary liver cancer. Hepatol Res 32:163-172, 2005.
  8. Ikai I,Arii S,Ichida T,Okazaki M,Okita K,Omata M,Kojiro M,Takayasu K,Nakanuma Y,Makuuchi M,Matsuyama Y,Monden M,Kudo M.Report of the 17th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 37:676-691, 2007.
  9. Ikai I, Kudo M, Arii S, Omata M, Kojiro M, Sakamoto M, Takayasu K, Hayashi N, Makuuchi M, Matsuyama Y, Monden M and for the Liver Cancer Study Group of Japan.Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res 40: 1043-1059, 2010.
  10. Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Matsui O, Matsuyama Y, and the Liver Cancer Study Group of Japan: Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res 46:372-390, 2016.
  11. Kudo M, Izumi N, Kubo S, T, Kokudo N, Sakamoto M, Shiina S, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, and the Takayama T: Report of the 20th follow-up survey of primary liver cancer in Japan. Hepatol Res 50:15-46, 2020.
  12. Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Kubo S: Report of the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan (2010-2011). Hepatol Res. 51:355-405, 2021
  13. Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Kubo S: Report of the 22nd nationwide follow-up survey of primary liver cancer in Japan (2012–2013). Hepatol Res 52:5-66, 2021.

研究論文(国内論文)

  1. 津熊 秀明, 藤本 伊三郎, 大島 明, 日本肝癌研究会. HBs抗原キャリアの肝細胞癌罹患リスク. 肝臓27: 1281-1289, 1986.

研究論文(国外論文)

  1. Liver Cancer Study Group of Japan: Predictive Factors for Long Term Prognosis after Partial Hepatectomy for Patients with Hepatocellular Carcinoma in Japan. Cancer 74:2772-2880, 1994.
  2. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y, Okita K, Yamada R. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 32:1224-1229, 2000.
  3. Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, Nakanuma Y, Okita K, Omata M, Takayasu K, Yamaoka Y. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 101:796-802, 2004.
  4. Takayasu K,Arii S,Ikai I,Omata M,Okita K,Ichida T,Matsuyama Y,Nakanuma Y,Kojiro M,Makuuchi M,Yamaoka Y,for Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131:461-469, 2006.
  5. Ikai I,Takayasu K,Omata M,Okita K,Nakanuma Y,Matsuyama Y,Makuuchi M,Kojiro M,Ichida T,Arii S,Yamaoka Y.A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma.J Gastroenterology 41:884-892, 2006.
  6. Minagawa M,Ikai I,Matsuyama Y,Yamaoka Y,Makuuchi M..Staging of Hepatocellular Carcinoma:assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 245:909-922, 2007.
  7. Eguchi S,Kanematsu T,Arii S,Okazaki M,Okita K,Omata M,Ikai I,Kudo M,Kojiro M,Makuuchi M,Monden M,Matsuyama Y,Nakanuma Y,Takayasu K,Liver Cancer Study Group of Japan. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey.Surgery 143:469-475, 2008.
  8. Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, Okita K, Omata M, Kudo M,Kojiro M, Nakanuma Y, Takayasu K, Monden M, Matsuyama Y, Ikai I and for the Liver Cancer Study Group of Japan.Surgical resection vs.percutaneous ablation for hepatocellular carcinoma:A preliminary report of the Japanese nationwide survey.J Hepatol 49:589-594, 2008.
  9. Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, Okita K, Omata M, Kudo M, Kojiro M, Nakanuma Y, Takayasu K, Monden M, Matsuyama Y, Ikai I and for the Liver Cancer Study Group of Japan.Hepatectomy versus radiofrequency ablation for early hepatocellular carcinoma : Reply. J Hepatol 50:1052-3, 2009.
  10. Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, Makuuchi M and for the Liver Cancer Study Group of Japan.Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: Propensity score analysis. AJR 194:830-837, 2010.
  11. Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y, Monden M and for the Liver Cancer Study Group of Japan.Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg 98:552-557, 2011.
  12. Higashi T, Hasegawa K, Kokudo K, Makuuchi M, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y, Sobue T. and for the Liver Cancer Study Group of Japan.Demonstration of quality of care measurement using the Japanese liver cancer registry. Hepatol Res 41:1208-1215, 2011.
  13. Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M and for the Liver Cancer Study Group of Japan.Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 56:886-892, 2012.
  14. Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y and for the Liver Cancer Study Group of Japan.Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 58:724-729, 2013.
  15. Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Ichida T, Nakashima O, Matsui O, Izumi N, Ku Y, Kokudo N, Makuuchi M and for the Liver Cancer Study Group of Japan.Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm. Liver International 33:762-770, 2013.
  16. Nouso K, Miyahara K Uchida D, Kuwaki K, Izumi N, Omata M, Ichida T, Kudo M, Ku Y, Kokudo N, Sakamoto M, Nakashima O, Takayama T, Matsui O, Matsuyama Y, Yamamoto K and for the Liver Cancer Study Group of Japan.Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan .Br J Cancer 109:1904-1907, 2013.
  17. Hasegawa K, Makuuchi M, Kokudo N, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima M, Matsui O, Matsuyama Y, for the Liver Cancer Study Group of Japan: Impact of histologically confirmed lymph node metastases on the patient survival after surgical resection for hepatocellular carcinoma: report of a Japanese nationwide survey. Ann Surg 259:166-170, 2014.
  18. Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M and for the Liver Cancer Study Group of Japan.Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to therapeutic impact. Ann Surg Feb 259:336-345, 2014.
  19. Aoki T, Kokudo N, Matsuyama Y, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Makuuchi M and for the Liver Cancer Study Group of Japan.Prognostic Impact of Spontaneous Tumor Rupture in Patients with Hepatocellular Carcinoma: an Analysis of 1,160 Cases from a Nationwide Survey in Japan. Annals of Surgery. Ann Surg Mar 259:532-542, 2014.
  20. Kitai S, Kudo M, Izumi N, Kaneko S, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Kadoya M, Matsuyama Y, Matsunaga T, for the Liver Cancer Study Group of Japan: Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score, and BCLC system) in 4,649 cases from a Japanese nationwide survey. Digest Dis 32:717-724, 2014.
  21. Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Takayama T, Kokudo N, for the Liver Cancer Study Group of Japan: A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: A nationwide study of 11, 950 patients. Ann Surg 261:513-520, 2015.
  22. Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Izumi N, Kadoya M, Kaneko S, Ku Y, Kudo M, Takayama T, Nakashima O, Liver Cancer Study Group of Japan: Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. Cancer 122:61-70, 2016.
  23. Kitai S, Kudo M, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M, for the Liver Cancer Study Group of Japan: Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis. Liver Cancer 5:175-189, 2016.
  24. Kudo M, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M, for the Liver Cancer Study Group of Japan: Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver Cancer 5:190-197, 2016.
  25. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Kokudo N: Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol 65:938-943, 2016.
  26. Toyoda H, Tada T, Johnson PJ, Izumi N, Kadoya M, Kaneko S, Kokudo N, Ku Y, Kubo S, Kumada T, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kudo M: Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. J Gastroenterol 52:1112-1121, 2017.
  27. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Kubo S, Sakamoto M, Nakashima O, Kumada T, Kokudo N; Liver Cancer Study Group of Japan: Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey. Hepatology 66:510-517, 2017.
  28. Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M, the Liver Cancer Study Group of Japan: Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in japan: the need for a more detailed evaluation of hepatic function. Liver Cancer 6:325-336, 2017.
  29. Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N; Liver Cancer Study Group of Japan: Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting. Liver Int 38:484-493, 2018.
  30. Kaibori M, Yoshii K, Hasegawa K, Ogawa A, Kubo S, Tateishi R, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N; Liver Cancer Study Group of Japan: Treatment optimization for hepatocellular carcinoma in elderly patients in a Japanese nationwide cohort. Ann Surg 270:121-130, 2019.
  31. Kaibori M, Yoshii K, Yokota I, Hasegawa K, Nagashima F, Kubo S, Kon M, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N: Liver Cancer Study Group of Japan: Impact of advanced age on survival in patients undergoing resection of hepatocellular carcinoma: report of a Japanese nationwide survey. Ann Surg 269:692-699, 2019.
  32. Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M and the Liver Cancer Study Group of Japan: Prediction of prognosis of intermediate stage HCC patients – validation of tumor marker score in nationwide database in Japan. Liver Cancer 8:403-411, 2019.
  33. Aoki T, Kubota K, Hasegawa K, Kubo S, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Nakashima O, Matsuyama Y, Murakami T, Kudo M; Liver Cancer Study Group of Japan: Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma. Br J Surg 107:113-120, 2020.
  34. Watanabe Y, Matsuyama Y, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, Takayama T, Nakashima O, Kudo M: Effect of surgical margin width after R0 resection for intrahepatic cholangiocarcinoma: A nationwide survey of the Liver Cancer Study Group of Japan: Surgery, 167:793-802, 2020.
  35. Fukami Y, Kaneoka Y, Maeda A, Kumada T, Tanaka J, Akita T, Kubo S, Izumi N, Kadoya M, Sakamoto M, Nakashima O, Matsuyama Y, Kokudo T, Hasegawa K, Yamashita T, Kashiwabara K, Takayama T, Kokudo N, Kudo M; Liver Cancer Study Group of Japan: Liver Resection for Multiple Hepatocellular Carcinomas: A Japanese Nationwide Survey. Ann Surg, 272:145-154, 2020.
  36. Aoki T, Kubota K, Kubo S, Eguchi S, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Nakashima O, Matsuyama Y, Murakami T, Kudo M: Analysis of patient outcome after non curative resection for hepatocellular carcinoma using nationwide survey data in Japan. World J Surg 45:607-614, 2021
  37. Takayama T, Yamazaki S, Matsuyama Y, Midorikawa Y, Shiina S, Izumi N, Hasegawa K, Kokudo N, Sakamoto M, Kubo S, Kudo M, Murakami T, Nakashima O, Liver Cancer Study Group of Japan: Prognostic grade for resecting hepatocellular carcinoma: a multicentre, retrospective study. Bri J Surg 108:412-418, 2021
  38. Kawaguchi Y, Hasegawa K, Hagiwara Y, De Bellis M, Famularo S, Panettieri E, Matsuyama Y, Tateishi R, Ichikawa T, Kokudo T, Izumi N, Kubo S, Sakamoto M, Shiina S, Takayama T, Nakashima O, Murakami T, Vauthey JN, Giulante F, De Carlis L, Romano F, Ruzzenente A, Guglielmi A, Kudo M, Kokudo N: Effect of diameter and number of hepatocellular carcinomas on survival after resection, trans-arterial chemoembolization, and ablation. Am J Gastroenterol, 116: 1698-1708, 2021.
  39. Kaibori M, Yoshii K, Kashiwabara K, Kokudo T, Hasegagwa K, Izumi N, Murakami T, Kudo M, Shiina S, Sakamoto M, Nakashima O, Matsuyama Y, Eguchi S, Yamashita T, Takayama T, Kokudo N, Kubo S: Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: report of a Japanese nationwide survey. Hepatol Res, 51: 90-901, 2021.

治療効果判定基準(国内論文)

  1. 肝臓治療直接効果判定基準 肝臓 35: 193-205, 1994.
  2. 日本肝癌研究会: 肝癌治療効果判定基準(2004改訂版).肝臓 45: 380-385, 2004.
  3. 日本肝癌研究会: 肝癌治療判定効果基準(2009年改訂版).肝臓 51:261-266, 2010
  4. 日本肝癌研究会: 肝癌治療判定効果基準(2015年改訂版).肝臓 56:116-121, 2015.
  5. 日本肝癌研究会: 肝癌治療判定効果基準(第5版)(2019年改訂版).肝臓60: 55-62, 2019.
  6. 日本肝癌研究会. 肝癌治療効果判定基準(第6版)(2021年改訂版).肝臓62: 823-829.2021

治療効果判定基準(国外論文)

  1. Kudo M, Kubo S, Takayasu K, Sakamoto M, Tanaka M, Ikai I, Furuse J, Nakamura K, Makuuchi M and for the Liver Cancer Study Group of Japan.Response evaluation criteria in cancer of the liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatol Res 40:686-692, 2010.
  2. Kudo M, Ueshima K, Kubo S, Sakamoto M, Tanaka M, Ikai I, Furuse J, Murakami T, Kadoya M, Kokudo N: Response evaluation criteria in cancer of the liver (RECICL) (2015 revised version). Hepatol Res 46:3-9, 2016.
  3. Kudo M, Ikeda M, Ueshima K, Sakamoto M, Shiina S, Tateishi R, Hasegawa K, Furuse J, Miyayama S, Murakami T, Yamashita T, Kokudo N: Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version). Hepatol Res 49:981-989, 2019.
  4. Kudo M, Ikeda M, Ueshima K, Sakamoto M, Shiina S, Tateishi R, Nouso K, Hasegawa K, Furuse J, Miyayama S, Murakami T, Yamashita T, Kokudo N: Response evaluation criteria in cancer of the liver (version 6) (RECICL 2021 revised version). Hepato Res 52:329-336, 2021.

転載許諾の申請について

お問い合わせ

お問い合わせフォーム

一般社団法人 日本肝癌研究会

〒589-8511
大阪府大阪狭山市大野東377-2
近畿大学医学部消化器内科
Tel:072-368-1901 Fax:072-368-1903